Format

Send to

Choose Destination
See comment in PubMed Commons below
J Affect Disord. 2002 Dec;72 Suppl 1:S23-34.

Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability.

Author information

1
Department of Psychiatry, Trafford General Hospital, Manchester, UK. jonathan@innervision.demon.co.uk

Abstract

Oxcarbazepine, although structurally similar to carbamazepine, is metabolised very differently. As a consequence, oxcarbazepine's pharmacokinetic profile is comparatively less complex, and a more predictable, linear relationship between oxcarbazepine and blood levels is apparent. Furthermore, hepatic enzyme induction is considerably less with oxcarbazepine. Unlike carbamazepine, oxcarbazepine does not appear to induce its own metabolism, nor is it highly protein bound. These pharmacokinetic and metabolic characteristics raise the expectation that potential for drug interactions and side effects with oxycarbazepine will be less than that reported for carbamazepine. This review compares the pharmacokinetic and metabolic profiles of the two drugs and the available efficacy and safety data of carbamazepine and oxcarbazepine, in the treatment of bipolar disorder.

PMID:
12589900
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center